Keywords: FDA, Roche, Avastin, Nomuura

US FDA Advisory Panel likely to focus on increased death risk associated with Roche’s Avastin, says Nomura

Article | 14 July 2010

Print This

Although investors are looking for the US Food and Drug Administration’s July 20 Advisory Panel to endorse tumor shrinkage (PFS) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in